Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.

PubWeight™: 1.93‹?› | Rank: Top 3%

🔗 View Article (PMID 12077264)

Published in J Immunol on July 01, 2002


Sander Zwaveling1, Sandra C Ferreira Mota, Jan Nouta, Mark Johnson, Grayson B Lipford, Rienk Offringa, Sjoerd H van der Burg, Cornelis J M Melief

Author Affiliations

1: Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.

Articles citing this

Cross-presentation by dendritic cells. Nat Rev Immunol (2012) 3.95

Development of TLR9 agonists for cancer therapy. J Clin Invest (2007) 2.64

TLR-based immune adjuvants. Vaccine (2010) 2.10

Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U S A (2008) 1.49

TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas. Blood (2012) 1.47

Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer (2016) 1.31

Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells. J Exp Med (2007) 1.28

Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther (2008) 1.24

Therapeutic cancer vaccines. J Clin Invest (2015) 1.23

The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J (2011) 1.19

Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs (2010) 1.18

Induction of interferon-gamma from natural killer cells by immunostimulatory CpG DNA is mediated through plasmacytoid-dendritic-cell-produced interferon-alpha and tumour necrosis factor-alpha. Immunology (2006) 1.09

HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med (2013) 1.02

BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses. Cancer Immunol Immunother (2012) 1.02

Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting function. J Immunother (2009) 1.01

Perspectives for preventive and therapeutic HPV vaccines. J Formos Med Assoc (2010) 0.99

Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies. Front Immunol (2015) 0.96

Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol Rev (2008) 0.96

Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents. Hum Gene Ther (2011) 0.96

Immunologic treatments for precancerous lesions and uterine cervical cancer. J Exp Clin Cancer Res (2014) 0.96

Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs (2012) 0.96

Peptide Vaccine: Progress and Challenges. Vaccines (Basel) (2014) 0.94

Understanding the biology of antigen cross-presentation for the design of vaccines against cancer. Front Immunol (2014) 0.93

Cancer immunotherapy targeting neoantigens. Semin Immunol (2015) 0.92

Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis. PLoS One (2015) 0.89

Therapeutic Vaccine Strategies against Human Papillomavirus. Vaccines (Basel) (2014) 0.89

Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice. J Virol (2004) 0.89

Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma. Head Neck (2012) 0.88

CpG Oligonucleotides as Cancer Vaccine Adjuvants. Vaccines (Basel) (2015) 0.87

Recombinant peptide replicates immunogenicity of synthetic linear peptide chimera for use as pre-erythrocytic stage malaria vaccine. Microbes Infect (2008) 0.87

Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. Vaccine (2007) 0.87

Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses. J Virol (2005) 0.87

The future of vaccines for cervical cancer. Gynecol Oncol (2008) 0.87

Therapeutic vaccines against human papillomavirus and cervical cancer. Open Virol J (2009) 0.85

Recent advances in the development of breast cancer vaccines. Breast Cancer (Dove Med Press) (2014) 0.85

Perspectives for therapeutic HPV vaccine development. J Biomed Sci (2016) 0.85

STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice. Cancer Immunol Immunother (2015) 0.84

Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proc Natl Acad Sci U S A (2015) 0.84

Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta Neuropathol Commun (2015) 0.84

Maximizing CD8+ T cell responses elicited by peptide vaccines containing CpG oligodeoxynucleotides. Clin Immunol (2007) 0.83

Effective colon cancer prophylaxis in mice using embryonic stem cells and carbon nanotubes. Int J Nanomedicine (2011) 0.83

Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. Expert Rev Vaccines (2016) 0.82

Carrageenan as an adjuvant to enhance peptide-based vaccine potency. Vaccine (2010) 0.82

PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity. Hum Vaccin Immunother (2016) 0.82

Immunization and immunotherapy for cancers involving infection by a human papillomavirus in a mouse model. Proc Natl Acad Sci U S A (2002) 0.81

Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine. Vaccines (Basel) (2015) 0.80

Enhancement of protein vaccine potency by in vivo electroporation mediated intramuscular injection. Vaccine (2010) 0.80

Intranasal immunization with a flagellin-adjuvanted peptide anticancer vaccine prevents tumor development by enhancing specific cytotoxic T lymphocyte response in a mouse model. Clin Exp Vaccine Res (2013) 0.79

Enhanced cross-presentation and improved CD8+ T cell responses after mannosylation of synthetic long peptides in mice. PLoS One (2014) 0.79

Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response. PLoS One (2014) 0.79

Characterization of Spontaneous Immune Responses against Long Peptides Derived from Bcl-X(L) in Cancer Patients Using Elispot. Cells (2012) 0.79

Current state in the development of candidate therapeutic HPV vaccines. Expert Rev Vaccines (2016) 0.79

Buccal injection of synthetic HPV long peptide vaccine induces local and systemic antigen-specific CD8+ T-cell immune responses and antitumor effects without adjuvant. Cell Biosci (2016) 0.79

Peptide Based Vaccine Approaches for Cancer-A Novel Approach Using a WT-1 Synthetic Long Peptide and the IRX-2 Immunomodulatory Regimen. Cancers (Basel) (2011) 0.78

Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination. Int J Biochem Cell Biol (2014) 0.78

Fowlpox virus recombinants expressing HPV-16 E6 and E7 oncogenes for the therapy of cervical carcinoma elicit humoral and cell-mediated responses in rabbits. J Transl Med (2010) 0.78

Progress in the development of a cervical cancer vaccine. Ther Clin Risk Manag (2006) 0.78

Preexisting CD4+ T-cell immunity in human population to avian influenza H7N9 virus: whole proteome-wide immunoinformatics analyses. PLoS One (2014) 0.77

Depletion of tumor-associated macrophages enhances the anti-tumor immunity induced by a Toll-like receptor agonist-conjugated peptide. Hum Vaccin Immunother (2014) 0.76

Improving Multi-Epitope Long Peptide Vaccine Potency by Using a Strategy that Enhances CD4+ T Help in BALB/c Mice. PLoS One (2015) 0.76

Priority Setting for Improvement of Cervical Cancer Prevention in Iran. Int J Health Policy Manag (2015) 0.76

A Human Papillomavirus Type 16 E6 52-62 CD4 T-Cell Epitope Restricted by the HLA-DR11 Molecule Described in an Epitope Hotspot. MOJ Immunol (2015) 0.76

Fusion of Hsp70 to Mage-a1 enhances the potency of vaccine-specific immune responses. J Transl Med (2013) 0.76

Targeting B-cell malignancies through human B-cell receptor specific CD4(+) T cells. Oncoimmunology (2016) 0.75

Design, Immune Responses and Anti-Tumor Potential of an HPV16 E6E7 Multi-Epitope Vaccine. PLoS One (2015) 0.75

Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8(+) and CD4(+) T-cell responses with multiple specificities including a novel DR7-restricted epitope. Oncoimmunology (2016) 0.75

Self-assembling peptides epitopes as a novel platform for anti-cancer vaccination. Mol Pharm (2017) 0.75

Design, automated synthesis and immunological evaluation of NOD2-ligand-antigen conjugates. Beilstein J Org Chem (2014) 0.75

Immunization with mutant HPV16 E7 protein inhibits the growth of TC-1 cells in tumor-bearing mice. Oncol Lett (2015) 0.75

Peptides and peptidomimetics as immunomodulators. Immunotherapy (2014) 0.75

Cancer Vaccines 2007. Cancer and HIV Vaccines: Shared Lessons. October 4-6, 2007, New York, USA. Abstracts. Cancer Immun (2008) 0.75

Immunogenic properties of recombinant and synthetic peptides of Human papillomavirus. Dokl Biochem Biophys (2008) 0.75

Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy. Oncoimmunology (2017) 0.75

Articles by these authors

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 5.79

Dendritic cell immunotherapy: mapping the way. Nat Med (2004) 4.28

Transcatheter valve-in-valve implantation for failed bioprosthetic heart valves. Circulation (2010) 3.65

A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature (2013) 3.46

The Fanconi anaemia gene FANCC promotes homologous recombination and error-prone DNA repair. Mol Cell (2004) 3.44

Extreme diving of beaked whales. J Exp Biol (2006) 2.95

Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol (2004) 2.80

A prospective, randomized, multicenter trial of amnioreduction vs selective fetoscopic laser photocoagulation for the treatment of severe twin-twin transfusion syndrome. Am J Obstet Gynecol (2007) 2.73

CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum (2003) 2.68

The vertebrate Hef ortholog is a component of the Fanconi anemia tumor-suppressor pathway. Nat Struct Mol Biol (2005) 2.55

Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography: an update for the U.S. Preventive Services Task Force. Ann Intern Med (2004) 2.53

Deep-diving foraging behaviour of sperm whales (Physeter macrocephalus). J Anim Ecol (2006) 2.41

Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med (2011) 2.39

The NIH genetic testing registry: a new, centralized database of genetic tests to enable access to comprehensive information and improve transparency. Nucleic Acids Res (2012) 2.35

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer (2008) 2.31

A double-blind randomized controlled clinical trial to assess the effect of Doppler optimized intraoperative fluid management on outcome following radical cystectomy. J Urol (2011) 2.19

An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell (2011) 2.14

Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res (2008) 2.06

Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res (2009) 2.04

M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol (2011) 2.02

MHC II in dendritic cells is targeted to lysosomes or T cell-induced exosomes via distinct multivesicular body pathways. Traffic (2009) 1.98

Mapping infant brain myelination with magnetic resonance imaging. J Neurosci (2011) 1.97

High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res (2007) 1.96

Control of spin precession in a spin-injected field effect transistor. Science (2009) 1.93

Ocular biomechanics and biotransport. Annu Rev Biomed Eng (2004) 1.91

Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res (2004) 1.90

Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers. Vaccine (2010) 1.88

Reducing DUI among US college students: results of an environmental prevention trial. Addiction (2005) 1.87

Mechanisms and treatment of cardiovascular disease in Williams-Beuren syndrome. J Clin Invest (2008) 1.86

Cystic adenomatoid malformation volume ratio predicts outcome in prenatally diagnosed cystic adenomatoid malformation of the lung. J Pediatr Surg (2002) 1.84

TLRs govern neutrophil activity in aspergillosis. J Immunol (2004) 1.83

Aging, age-related macular degeneration, and the response-to-retention of apolipoprotein B-containing lipoproteins. Prog Retin Eye Res (2009) 1.80

Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J Immunol (2008) 1.78

The changing paradigm of outflow resistance generation: towards synergistic models of the JCT and inner wall endothelium. Exp Eye Res (2008) 1.77

Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol (2011) 1.71

Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A (2010) 1.67

Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol (2002) 1.66

Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res (2008) 1.66

The oil spill in ageing Bruch membrane. Br J Ophthalmol (2011) 1.62

Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. Cancer Res (2010) 1.59

Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol (2009) 1.56

Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res (2008) 1.54

CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol (2007) 1.54

Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci U S A (2007) 1.53

Characterising the complexity of medication safety using a human factors approach: an observational study in two intensive care units. BMJ Qual Saf (2013) 1.52

Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res (2004) 1.51

Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res (2005) 1.49

Multidetector computed tomography in transcatheter aortic valve implantation. JACC Cardiovasc Imaging (2011) 1.47

FANCE: the link between Fanconi anaemia complex assembly and activity. EMBO J (2002) 1.47

Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas. J Immunol (2002) 1.46

The mechanism of increasing outflow facility during washout in the bovine eye. Invest Ophthalmol Vis Sci (2002) 1.44

Residency training in preventive medicine: challenges and opportunities. Am J Prev Med (2005) 1.44

Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics. FEBS J (2009) 1.41

Apolipoprotein B-containing lipoproteins in retinal aging and age-related macular degeneration. J Lipid Res (2009) 1.41

Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res (2003) 1.40

Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res (2011) 1.39

Can the Kattan nomogram still accurately predict prognosis in renal cell carcinoma using the revised 2010 tumor-nodes-metastasis reclassification? Int J Urol (2012) 1.38

On-film formation of bi nanowires with extraordinary electron mobility. Nano Lett (2009) 1.38

Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res (2005) 1.38

Quick-freeze/deep-etch visualization of age-related lipid accumulation in Bruch's membrane. Invest Ophthalmol Vis Sci (2003) 1.36

Hierarchical modeling for rare event detection and cell subset alignment across flow cytometry samples. PLoS Comput Biol (2013) 1.35

Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation. Laryngoscope (2002) 1.35

CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci U S A (2002) 1.34

Analysis of Mycobacterium tuberculosis-specific CD8 T-cells in patients with active tuberculosis and in individuals with latent infection. PLoS One (2009) 1.33

Individual right whales call louder in increased environmental noise. Biol Lett (2010) 1.31

Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res (2005) 1.30

Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. Microbes Infect (2002) 1.30

Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J Immunol (2004) 1.29

Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res (2013) 1.28

Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells. J Exp Med (2007) 1.28

Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur J Immunol (2010) 1.27

Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res (2009) 1.27